Strumento inattivo

Altre lingue Neos Therapeutics, Inc.

Azioni

NEOS

US64052L1061

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Aytu Biopharma, Inc. Enters into Loan and Security Agreement, by and Among Neos Therapeutics, Inc., Neos Therapeutics Brands, Llc, Neos Therapeutics, Lp, Neos Therapeutics Commercial, Llc, Pharmafab Texas, Llc, Aytu Therapeutics, Llc, Innovus Pharmaceuticals, Inc., Semprae Laboratories, Inc., Novalere, Inc., Supplement Hunt, Inc., and Delta Prime Savings Club, Inc. as Borrowers	31/01/22
Aytu BioScience : Completes Merger With Neos Therapeutics	22/03/21
NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements (form 8-K)	22/03/21
Neos Therapeutics, Inc. Announces Board Changes	22/03/21
Neos Therapeutics, Inc. Announces Cessation of Richard Eisenstadt as Chief Financial Officer	22/03/21
Neos Therapeutics, Inc. Announces Cessation of Gerald Mclaughlin as Chief Executive Officer	22/03/21
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from S&P TMI Index	22/03/21
Neos Therapeutics : Aytu BioScience Announces Close of Merger with Neos Therapeutics	22/03/21
Neos Therapeutics, Inc.(NasdaqGM:NEOS) dropped from NASDAQ Composite Index	19/03/21
Aytu BioScience, Inc. completed the acquisition of Neos Therapeutics, Inc..	19/03/21
Neos Therapeutics : Merger With Aytu BioScience Endorsed by Proxy Advisers Glass, Lewis	12/03/21
Glass Lewis, a Leading Independent Proxy Advisory Firm, Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	12/03/21
Leading Independent Proxy Advisory Firm ISS Recommends Neos Therapeutics Stockholders Vote “FOR” the Pending Merger With Aytu BioScience	10/03/21
Aytu BioScience : Neos Therapeutics Shareholders To Vote on Deal In March	10/02/21
Aytu BioScience and Neos Therapeutics Announce Special Meetings of Stockholders Related to Proposed Merger to Be Held on March 18, 2021	10/02/21
NEOS THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	08/02/21
Neos Therapeutics, Inc. announced that it has received $5 million in funding from Aytu BioScience, Inc.	08/02/21
NEOS THERAPEUTICS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	11/01/21
Neos Therapeutics to Present at H.C. Wainwright Virtual BioConnect Conference	04/01/21
NEOS THERAPEUTICS, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)	30/12/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Neos Therapeutics, Inc.

Azioni

NEOS

US64052L1061

Altre lingue

Filtri